4 treatment settings, 4 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
ESA if serum EPO <500; luspatercept first line (COMMANDS) or after ESA failure (MEDALIST); imetelstat after ESA failure (IMerge); lenalidomide for del(5q).
An injection that helps the marrow finish making red cells, reducing or removing the need for transfusions in lower-risk MDS and beta-thalassaemia.
Imetelstat is a lipid-linked oligonucleotide that binds the RNA template of telomerase, the enzyme cancer cells use to stay immortal, and it is the first telomerase inhibitor approved for any cancer. In lower-risk myelodysplastic syndromes it freed 40% of transfusion-dependent patients from transfusions for at least eight weeks versus 15% on placebo.
Lenalidomide is a thalidomide descendant that glues the proteins IKZF1 and IKZF3 to cereblon so the cell destroys them, killing plasma cells and rousing T cells. It is the backbone of myeloma treatment and maintenance, also used in mantle cell and follicular lymphoma, and generic since 2022.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · With dexamethasone after at least one prior therapy, the label's two randomised studies, N=353; 3% with placebo and dexamethasone | - | 33% |
| Deep vein thrombosis · With dexamethasone after at least one prior therapy, the label's two randomised studies, N=353; 4% any grade with placebo and dexamethasone | 9% | 8% |
| Haematological second primary malignancy · Maintenance after high-dose melphalan and autologous transplant, the label's two maintenance studies; 3.3% with placebo | 7.5% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Allogeneic HSCT, usually after hypomethylating-agent cytoreduction; BMT CTN 1102 showed a survival benefit for transplant in 50-75-year-olds.
Allogeneic stem cell transplantation replaces a patient's blood system with a donor's after conditioning chemotherapy, so donor immune cells hunt down leukaemia left behind. It remains the only cure for adverse-risk acute myeloid leukaemia, high-risk acute lymphoblastic leukaemia and Richter transformation, at the price of graft-versus-host disease.
A gentle chemotherapy that switches silenced genes back on. With venetoclax it became the standard for older people with AML who cannot take intensive treatment.
Averages across everyone diagnosed, often years ago. A median is the middle of a group: half the people counted lived longer than the figure shown, and some lived far longer. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · VIALE-A, azacitidine with venetoclax (28% with azacitidine and placebo) | - | 42% |
| Febrile neutropenia · VIALE-A, azacitidine with venetoclax (19% with azacitidine and placebo) | - | 42% |
| Nausea · VIALE-A, azacitidine with venetoclax (35% with azacitidine and placebo) | 44% | - |
| Injection-site reactions · Subcutaneous azacitidine alone in myelodysplastic syndromes (US label Study 4, N=175); injection-site erythema 43% | 29% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Azacitidine (AZA-001) or decitabine / oral decitabine-cedazuridine until progression; supportive care and trials.
A gentle chemotherapy that switches silenced genes back on. With venetoclax it became the standard for older people with AML who cannot take intensive treatment.
Oral decitabine-cedazuridine is a pill version of the hypomethylating chemotherapy that, since May 2026, lets older AML patients take their whole venetoclax regimen at home.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · VIALE-A, azacitidine with venetoclax (28% with azacitidine and placebo) | - | 42% |
| Febrile neutropenia · VIALE-A, azacitidine with venetoclax (19% with azacitidine and placebo) | - | 42% |
| Nausea · VIALE-A, azacitidine with venetoclax (35% with azacitidine and placebo) | 44% | - |
| Injection-site reactions · Subcutaneous azacitidine alone in myelodysplastic syndromes (US label Study 4, N=175); injection-site erythema 43% | 29% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Transfusion, iron chelation for transfusional iron overload (TELESTO), infection management, G-CSF for neutropenic infection.
Red cell and platelet transfusions, iron and erythropoiesis-stimulating agents keep patients safe through chemotherapy and marrow failure; restrictive thresholds and ESA caution reflect trials showing more is not better.
Granulocyte colony-stimulating factor medicines support neutrophil production and recovery. Their use depends on the treatment regimen, infection risk and individual clinical context.
Averages across everyone diagnosed, often years ago. A median is the middle of a group: half the people counted lived longer than the figure shown, and some lived far longer. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
Add these to your appointment list, or take the full question set for this cancer.